TrumpLyftAlles | 11 points
ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19 (Broward County, FL USA 2020-06-06)https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v1
[-] TrumpLyftAlles | 1 points
Another article about this study, with a good quote by Dr Hibberd.
US trial of ivermectin cuts coronavirus mortality by 40%
A US clinical trial of the drug ivermectin found that it reduced the mortality rate of COVID-19 patients by 40%.
This study was published in medRxiv and was led by Dr Jean-Jacques Rajter a physician at Broward Health Medical Center. The study assessed 280 coronavirus patients over the age of 18, with 173 being treated with the drug and 107 having standard care for the virus. The study found that overall mortality in those who took the treatment was 15% compared to those who did not take it, who had a 25% mortality rate. This would equate to a 40% drop overall.
The most notable result in the study showed that the drug had a significant effect on the very high risk group of COVID-19 patients suffering from severe pulmonary disease. Of the patients who did not receive ivermectin, 81% died, while only 39% died when receiving the treatment, improving their survival odds by just over 50%.
Ivermectin was developed in the 1970s as a new class of drug to treat parasitic infections. It was initially used in veterinary medicine before being used to treat onchocerciasis and lymphatic filariasis. 3.7 billion doses are estimated to have been given since its approval. It has also been studied as a potential treatment for influenza and HIV.
Dr Peter Hibberd, a board certified emergency medicine physician, said on the trial: “This drug has been used for over 30 years by millions of people around the world and has a marked safety base. We understand fully its side effects, and the effect of a single dose in such a critically diseased state cannot be ignored. That’s why the results were so surprising, because these people had damage in their lungs with a rapidly downhill progression and their clinical course stabilised within 24 to 48 hours.” The study is still up for peer review, but if this and future studies prove accurate the drug could be a significant advancement in treating COVID-19 patients.
[-] TrumpLyftAlles | 1 points
NewsMax:
US Trial Finds Drug Cuts Coronavirus Mortality 40%
New information:
Preliminary findings released Tuesday for a U.S.-based clinical trial of anti-parasite drug ivermectin found that the mortality rate for coronavirus patients fell 40%, according to the Medrxiv.org site. The ivermectin study -- it began in March as part of a larger Australian-led clinical study -- focused on 280 patients, 173 of whom were treated with the drug at four Broward County, Florida, hospitals.
The research team was led by Dr. Jean-Jacques Rajter, a Broward Health Medical Center physician, and his wife, Juliana Cepelowicz Rajter.
The findings reported in Medrxiv, “ICON (Ivermectin in COVID-19) Study: Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With COVID-19,” said that patients who took part in the trial were given a single dose of the anti-parasitic medication, and some received a second dose a week later.
The dose given the COVID-19 patients was the same as the FDA-approved dose used to treat patients with intestinal parasites.
The FDA has NOT approved ivermectin for humans, just animals. The CDC mentions that their recommendation of ivermectin to treat scabies is not FDA approved. I think the dose must come from the CDC.
According to Medrxiv.org, the Broward study found that overall mortality among seriously ill COVID-19 patients treated with the drug was 15%. Mortality among patients in a similar disease state who did not receive ivermectin was 25%.
That would equate to a 40% drop in mortality, a statistically significant difference.
“It’s amazing and could literally pull people back from critical COVID-19 illness,” according to board certified emergency medicine physician Dr. Peter Hibberd, M.D.
Ivermectin is a life-saver for those who are near-dying.
In an interview Tuesday, Hibberd hailed the results as a “major breakthrough in COVID-19 management.”
If reviewed successfully, Ivermectin could become the first COVID-19 therapy shown to reduce mortality risk in seriously ill patients in a clinical trial.
A previous therapeutic medication, remdesivir, has already won FDA emergency use authorization. Trials showed remdesivir shortened patients’ hospital stays, but did not show a statistically significant improvement in reducing overall mortality, according to the National Institutes of Health.
“Even if it was judged to need a second dose in seven days,” Hibberd said, “it remains a breakthrough in COVID-19 management.”
Another $5? Ivermectin is cheap.
Medical experts aren’t sure yet precisely how the drug counters COVID-19. Some suspect it could be blocking a protein that the virus requires in order to reproduce.
This: ivermectin binds to the alpha/beta dimers that the virus otherwise uses to enter the nucleus where it replicates. See the MedCram video #52.
Perhaps the study’s most impressive finding: The effect the drug had on 75 sick COVID-19 patients who were suffering from “severe pulmonary disease” – a very high-risk group.
Of patients in that group who did not receive ivermectin, 81% died. Yet the mortality rate for patients with severe pulmonary disease who did receive ivermectin was 39 percent.
In other words, for the most severely ill patients with severe pulmonary disease, the use of ivermectin improved the odds of survival by just over 50%.
As news of ivermectin -- which is used globally to treat scabies, lice and other parasitic diseases -- has spread on the internet, the FDA has warned patients against trying to treat themselves with it.
The FDA on May 1 posted the following advisory: “While there are approved uses for ivermectin in people and animals, it is not approved for the prevention or treatment of COVID-19.” Ivermectin is generally considered safe, however, the FDA warned consumers to never use any form of the drug intended for use by animals.
There is literally NO proof of the animal version being dangerous. 18 people report consuming the horse paste form of ivermectin in Amazon reviews.
Hibberd said that once the study is peer-reviewed, he would like to see the FDA grant emergency-use authorization for ivermectin as a coronavirus treatment – to be used under expert medical supervision -- as soon as possible.
When used as prescribed, he said, ivermectin has a very strong safety record.
“This drug has been used for over 30 years by millions of people around the world, and has a marked safety base,” he told Newsmax. “We understand fully its side effects, and the effect of a single dose in such a critically diseased state cannot be ignored.”
Hibberd tells Newsmax that several major U.S. medical centers already list ivermectin as a COVID-19 treatment. It is also reportedly being used to fight the virus in Bolivia, Peru, India, and other nations.
Over a dozen clinical trials of the drug are also reportedly underway in Egypt, Iraq, Argentina, Brazil, Mexico and Australia.
25 at last count.
Ivermectin first emerged as a possible coronavirus therapeutic when a study by researchers from Royal Melbourne University and Monash University in Victoria, Australia showed the drug wiped out the virus in a test tube.
Noting patients who received the drug in the Broward County study were already quite ill, Hibberd suggested that giving ivermectin to patients earlier in the disease cycle could be even more beneficial, and might even help them avoid hospitalization altogether.
“That’s why the results were so surprising,” he told Newsmax, “because these people already had damage in their lungs with a rapidly downhill progression.”
“Some of these patients were in extreme distress and rapidly going downhill,” he added, “and their clinical course stabilized with 24 to 48 hours.”
Some patients went home three to four days after receiving treatment, he said.
[-] fyodor32768 | 2 points
who is Hibberd? Is he actually using Ivermectin on patients? Is he talking about patients in the study? Is he just some guy that Newsmax goes to for quotes?
[-] TrumpLyftAlles | 1 points
Hibberd tells Newsmax that several major U.S. medical centers already list ivermectin as a COVID-19 treatment. It is also reportedly being used to fight the virus in Bolivia, Peru, India, and other nations.
All google tells me is that he lives in Palm Beach County, not Broward, and "Peter Hibberd ivermectin" only turns up NewsMax stories, directly or indirectly -- so it appears that he IS an expert that NewsMax turns to.
On the other hand, he appears well-informed, better than me, if this statement is true:
Hibberd tells Newsmax that several major U.S. medical centers already list ivermectin as a COVID-19 treatment.
I don't know of ANY US hospitals using ivermectin except one at the University of Kentucky.
The rest of his statements about ivermectin are spot on, so he's obviously interested in the drug.
This suggests that he is either using the drug to treat patients, and doesn't want to say so because it's off-label for covid19, or he's talking to the Broward MDs. Palm Beach Country is adjacent to Broward.
“Some of these patients were in extreme distress and rapidly going downhill,” he added, “and their clinical course stabilized with 24 to 48 hours.”
Edit (2020-06-16): A couple days ago I exchanged tweets with Hibberd. He said that he talks to the Broward doctors regularly.
[-] TrumpLyftAlles | 1 points
Looking at Google trends 10 days after this study was published -- it didn't produce a ripple of interest in ivermectin. :(
The big peak is when the Monash 48 hours study was published. That's the only ivermectin study that's gotten a lot of interest.
[-] jetplane10-102 | 1 points
Ivermectin is cheap, safe to use & effective to treat & prevent covid19, based on people's observations around the world. Resistance to this cure & preventative is due to the patent having expired. Big drug companies won't get paid. Government are complicite in ignoring the Ivermectin treatment, they are allowing death & injury to patients & health care workers.
I hope they get sued for it. I find their behaviour disgusting.
[-] TrumpLyftAlles | 1 points | Jun 10 2020 15:53:07
Mortality was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%, OR 0.15, CI 0.05-0.47, P=.001)
O frabjous day! Callooh! Callay! Ivermectin works! :)
This is the study long-promised by the Broward County MD who made news about his success with ivermectin in mid-April, which made a big splash in conservative circles when NewMax ran a May 22 story about a study being submitted review.
It's great news! Unfortunately, not a RCT (Random Controlled Trial) but valuable nonetheless:
Ivermectin is very helpful to patients with severe covid19 symptoms
This result that ivermectin is most helpful to the sickest patients is also indicated by the Sermo chart of about 70 MDs applying ivermectin: In the ICU, 57% found ivermectin to be Extremely Effective or Very Effective (EEVE), and another 36% found it to be Moderately Effective. Those MDs rated ivermectin as only 25% EEVE among hospitalized patients (outside the ICU) and 41% EEVE among NOT hospitalized patients.
#Abstract Abstract Importance: No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2. Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in vitro but clinical response has not been previously evaluated. #Objective: To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19.
#Design and Setting: Retrospective cohort study of consecutive patients hospitalized at four Broward Health hospitals in South Florida with confirmed SARS-CoV-2. Enrollment dates were March 15, 2020 through May 11, 2020. Follow up data for all outcomes was May 19, 2020.
#Participants: 280 patients with confirmed SARS-CoV-2 infection (mean age 59.6 years [standard deviation 17.9], 45.4% female), of whom 173 were treated with ivermectin and 107 were usual care were reviewed. 27 identified patients were not reviewed due to multiple admissions, lack of confirmed COVID results during hospitalization, age less than 18, pregnancy, or incarceration.
Pretty old cohort. Using the mean and standard deviation here the normal distribution (which may or may not apply) looks like this. The distribution was probably skewed toward older patients.
173 treated vs 107 not treated: pretty solid, except treatment was given to the sickest patients instead of being randomly assigned.
#Exposure: Patients were categorized into two treatment groups based on whether they received at least one dose of ivermectin at any time during the hospitalization. Treatment decisions were at the discretion of the treating physicians. Severe pulmonary involvement at study entry was characterized as need for either FiO2 ≥50%, or noninvasive or invasive mechanical ventilation.
Ivermectin was given to the patients with the most severe course of disease. From here: " FiO2 is defined as the concentration of oxygen that a person inhales."
#Main Outcomes and Measures: The primary outcome was all-cause in-hospital mortality. Secondary outcomes included subgroup mortality in patients with severe pulmonary involvement and extubation rates for patients requiring invasive ventilation.
Extubation is removing the tube that is inserted when patients are put on ventilators, the opposite as intubation.
Results:
Univariate analysis showed lower mortality in the ivermectin group (25.2% versus 15.0%, OR 0.52, 95% CI 0.29-0.96, P=.03).
"Univariate analysis is the simplest form of analyzing data. “Uni” means “one”, so in other words your data has only one variable. It doesn't deal with causes or relationships (unlike regression) and it's major purpose is to describe; it takes data, summarizes that data and finds patterns in the data."
Without adjusting for anything, ivermectin lowered the fatality rate 10.2%.
Mortality was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%, OR 0.15, CI 0.05-0.47, P=.001),
It's not clear if "severe pulmonary disease" is about covid19 symptoms. My guess is that these patients had other problems, like COPD. Use of ivermectin began in mid-March, when covid19 was primarily perceived as a lung disease.
For these patients, ivermectin reduced the fatalities by 41%.
N=75 is a lot (in the context of ivermectin trials) and the highly-significant result (p=.001) reflects both the impact of ivermectin and that nice big N.
but there was no significant difference in successful extubation rates (36.1% vs 15.4%, OR 3.11 (0.88-11.00), p=.07).
With ivermectin, 20.7% more patients got off ventilators, but this result is barely statistically insignificant, applying the usual standard of p= .05, which is just a tradition. Sample size is a major determinant of statistical significance. If they had another 2-3 patients it might have met the standard.
After adjustment for between-group differences and mortality risks, the mortality difference remained significant for the entire cohort (OR 0.27, CI 0.09-0.85, p=.03; HR 0.37, CI 0.19-0.71, p=.03).
This is a multivariate analysis. The report doesn't disclose what they controlled for. The p=.03 is the same as the univariate analysis result.
#Conclusions and Relevance: Ivermectin was associated with lower mortality during treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory support. These findings require randomized controlled trials for confirmation.
The RCTs are coming! :)
permalink